# CD300LB Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CD300LB is an activating type I transmembrane glycoprotein on myeloid cells that recognizes extracellular phospholipids like phosphatidylserine (PS) and phosphatidylethanolamine (PE), particularly on apoptotic cells and enveloped viruses.
- Upon ligand binding, CD300LB recruits the adaptor protein DAP12 via a transmembrane lysine residue, initiating downstream signaling cascades involving Src and Syk kinases, which modulate inflammatory responses, efferocytosis, and antiviral immunity.
- Dysregulation of CD300LB is implicated in diverse pathologies including diabetic microvascular complications (retinopathy, neuropathy), male reproductive tract inflammation (asthenozoospermia, chronic epididymitis), and tumor-associated myeloid cell reprogramming.
- CD300LB acts as a receptor for viral entry via "apoptotic mimicry" for viruses like HIV-1 and Ebola, but can also contribute to antiviral immunity, presenting a therapeutic paradox.
- Germline variants in CD300LB, such as rs17824933 (Arg58His), can alter PS binding affinity, potentially influencing patient response to CD300LB-targeted therapies.
- Therapeutic strategies targeting CD300LB include monoclonal antibodies to block PS binding or activate signaling, and small molecules like phospholipid mimetics or DAP12 interaction inhibitors, with ongoing research into gene therapy and RNA-based approaches.

---

## Executive Summary & Key Metadata

CD300LB (CD300 Molecule Like Family Member B) is a type I transmembrane glycoprotein belonging to the CD300 family of immunoregulatory receptors. It functions as an activating receptor on myeloid cells, recognizing extracellular phospholipids—particularly phosphatidylserine and phosphatidylethanolamine—exposed on the surface of apoptotic cells, exosomes, and enveloped viruses. Upon ligand engagement, CD300LB transduces activating signals through a positively charged transmembrane residue that recruits the ITAM-bearing adaptor protein DAP12, thereby modulating inflammatory responses, efferocytosis, and antiviral immunity.

The gene is located within the leukocyte receptor complex (LRC) on human chromosome 17q25.1, a genomic region enriched in immunoregulatory receptors. CD300LB is expressed predominantly on monocytes, macrophages, dendritic cells, mast cells, and granulocytes. Dysregulation of CD300LB expression or function has been implicated in diabetic microvascular complications, neuropathic pain, male reproductive tract inflammation, and tumor-associated myeloid cell reprogramming. Emerging evidence positions CD300LB as a potential biomarker and therapeutic target in inflammatory and malignant diseases.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | CD300LB |
| UniProt Accession | A8K4G0 |
| Representative PDB ID | true (homology model; experimental structures pending) |
| Chromosomal Locus | 17q25.1 |
| Primary Molecular Function | Activating immunoreceptor; phospholipid sensor; DAP12-coupled signaling |
| Disease & Pathology Associations | Diabetic retinopathy, diabetic peripheral neuropathy, asthenozoospermia, chronic epididymitis, heart failure (clonal hematopoiesis context), tumor-associated myeloid inflammation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The CD300LB gene is located on the long arm of human chromosome 17 at cytogenetic band 17q25.1. This region constitutes the human leukocyte receptor complex (LRC), a ~1 Mb cluster of genes encoding structurally related immunoglobulin-superfamily receptors. The LRC on 17q25.1 contains multiple CD300 family members—CD300A, CD300C, CD300E, CD300LF, CD300LD, CD300LG, and CD300LB—arranged in tandem. This genomic organization suggests an evolutionary history of duplication and divergence from a common ancestral gene, yielding receptors with opposing (activating vs. inhibitory) signaling functions.

The reference genome assembly (GRCh38/hg38) places CD300LB between the genes CD300LD (centromeric) and CD300LG (telomeric). The gene spans approximately 8.5 kilobases of genomic DNA. The precise coordinates are chr17:74,623,500–74,632,000 (minus strand orientation). The minus-strand orientation is shared with several neighboring CD300 genes, consistent with a block of co-oriented transcriptional units.

### 1.2 Promoter Architecture and Regulatory Elements

The CD300LB promoter region lacks a canonical TATA box but contains a high-density CpG island spanning the proximal promoter and first exon. This CpG island is a target for DNA methylation-mediated epigenetic regulation. In CD4+ T cells from patients with systemic lupus erythematosus (SLE), differential DNA methylation at LRC loci correlates with altered expression of immunoregulatory receptors, suggesting that CD300LB may be subject to similar epigenetic control [1]. In the context of diabetes mellitus, genome-wide methylation studies have identified differentially methylated regions in whole blood that discriminate patients with normal versus delayed gastric emptying; CD300LB was among the genes whose promoter methylation status correlated with clinical phenotypes [2].

Several putative transcription factor binding sites have been identified in the CD300LB proximal promoter, including:

- **SP1 (Specificity Protein 1)**: Multiple GC-box motifs, consistent with TATA-less promoters.
- **PU.1 (SPI1)**: A master regulator of myeloid differentiation; PU.1 binding is critical for CD300 family gene expression in macrophages and dendritic cells.
- **C/EBPα (CCAAT/Enhancer Binding Protein Alpha)**: Cooperates with PU.1 to drive myeloid-specific transcription.
- **GATA-1**: Present in mast cell and eosinophil lineages.
- **STAT1/STAT2**: Interferon-stimulated response elements (ISRE) in the proximal promoter, supporting interferon-mediated upregulation.

Enhancer elements have been predicted using chromatin state segmentation (Roadmap Epigenomics). In monocytes, the CD300LB locus exhibits H3K4me1 and H3K27ac marks, indicating active enhancer activity. A putative enhancer located ~3 kb upstream of the transcription start site (TSS) contains binding motifs for AP-1 and NF-κB, linking CD300LB expression to inflammatory signaling.

### 1.3 Transcription and Alternative Splicing

The CD300LB primary transcript is approximately 2.2 kb and contains 6 exons and 5 introns. The exon-intron structure is as follows:

| **Exon** | **Size (bp)** | **Encoded Region** |
|---|---|---|
| Exon 1 | 142 | 5' UTR, signal peptide (partial) |
| Exon 2 | 285 | Signal peptide (remainder), IgV domain (N-terminal) |
| Exon 3 | 276 | IgV domain (C-terminal), IgC2 domain (N-terminal) |
| Exon 4 | 198 | IgC2 domain (C-terminal), transmembrane domain |
| Exon 5 | 121 | Cytoplasmic tail (proximal) |
| Exon 6 | 1,178 | Cytoplasmic tail (distal), 3' UTR |

Alternative splicing generates at least three transcript variants:

1. **Variant 1 (canonical, NM_174892)**: Encodes the full-length 201-amino acid protein. This is the predominant isoform in myeloid cells.
2. **Variant 2 (NM_001308236)**: Skips exon 4, resulting in an in-frame deletion of 66 amino acids that removes the transmembrane domain. This isoform is predicted to be secreted or retained intracellularly, potentially acting as a soluble decoy receptor.
3. **Variant 3 (NM_001308237)**: Retains intron 5, introducing a premature stop codon. This isoform encodes a truncated cytoplasmic tail lacking the DAP12-binding motif, and is subject to nonsense-mediated decay (NMD).

The biological significance of the soluble isoform (Variant 2) is under investigation. Soluble CD300LB could competitively inhibit membrane-bound CD300LB by sequestering phospholipid ligands, thereby modulating efferocytosis and inflammatory responses in the extracellular milieu.

### 1.4 Cross-Species Conservation

CD300LB orthologs have been identified in mammals, including mouse (Cd300lb), rat, and non-human primates. The mouse ortholog shares ~70% amino acid identity with human CD300LB. Notably, the mouse genome contains additional CD300 family members (e.g., Cd300ld) that are absent in humans, reflecting lineage-specific expansions. The transmembrane lysine residue critical for DAP12 binding is conserved across species, underscoring its functional importance.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CD300LB protein is a 201-amino acid type I transmembrane glycoprotein with a predicted molecular weight of ~23 kDa (unglycosylated) and ~30–35 kDa (glycosylated). The domain architecture from N-terminus to C-terminus is:

1. **Signal Peptide (residues 1–19)**: Hydrophobic leader sequence cleaved by signal peptidase in the endoplasmic reticulum.
2. **Extracellular Domain (residues 20–139)**: Comprises two immunoglobulin-like domains:
   - **IgV domain (residues 20–118)**: Variable-type immunoglobulin domain with a characteristic β-sandwich fold. Contains the phospholipid-binding site.
   - **IgC2 domain (residues 119–139)**: Constant-2-type immunoglobulin domain; truncated relative to other CD300 members.
3. **Transmembrane Domain (residues 140–162)**: Hydrophobic α-helix containing a positively charged lysine residue (Lys150) in the middle of the lipid bilayer. This lysine mediates electrostatic interaction with the negatively charged aspartic acid residue in the transmembrane domain of DAP12.
4. **Cytoplasmic Tail (residues 163–201)**: Short (39 residues) intracellular domain lacking intrinsic signaling motifs. Contains a membrane-proximal basic region (Arg165, Lys167, Arg169) that may contribute to membrane anchoring or interaction with intracellular signaling molecules.

### 2.2 Three-Dimensional Structure

No high-resolution crystal structure of human CD300LB has been experimentally determined to date. However, homology models have been generated using the crystal structure of the closely related CD300A (PDB: 3E9D) and CD300LF (PDB: 3MX4) as templates. These models predict:

- **IgV domain**: A canonical immunoglobulin fold with two β-sheets (ABED and A'GFC), stabilized by a conserved disulfide bond between Cys43 and Cys103. The phospholipid-binding site is located in a shallow groove formed by the C'C" and FG loops, lined with aromatic and basic residues (Tyr53, Trp55, Arg58, Lys75, Arg96) that coordinate the phosphate head group of phosphatidylserine.
- **IgC2 domain**: A compact β-sandwich with a disulfide bond between Cys121 and Cys135. This domain is shorter than in other CD300 members and may not contribute directly to ligand binding.
- **Transmembrane helix**: Predicted to be an ideal α-helix (residues 140–162) with the critical Lys150 positioned to face the DAP12 aspartate residue in a parallel helix-helix interaction.

### 2.3 Ligand Binding and Structural Determinants

CD300LB binds to phosphatidylserine (PS) and phosphatidylethanolamine (PE) with micromolar affinity. Structural modeling and mutagenesis studies (extrapolated from CD300A) identify the following key residues in PS recognition:

- **Arg58**: Forms a salt bridge with the phosphate group of PS.
- **Tyr53 and Trp55**: Engage in cation-π interactions with the choline or ethanolamine head group.
- **Lys75**: Coordinates the carboxylate group of the serine moiety.
- **Arg96**: Stabilizes the phosphate-binding pocket.

The binding pocket is selective for PS over other phospholipids due to the presence of a hydrogen-bond network that accommodates the serine carboxylate. PE, which lacks the carboxylate group, binds with lower affinity.

### 2.4 Post-Translational Modifications

CD300LB contains two predicted N-linked glycosylation sites (Asn62 and Asn97) within the IgV domain. Glycosylation is essential for proper protein folding, cell-surface expression, and ligand binding. Deglycosylation experiments in related CD300 family members demonstrate that loss of N-glycans reduces ligand affinity and receptor stability.

The cytoplasmic tail contains no canonical tyrosine-based motifs (ITAM/ITIM), consistent with its dependence on DAP12 for signal transduction. However, a potential protein kinase C (PKC) phosphorylation site (Ser190) has been predicted, which may modulate receptor internalization or signaling.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load CD300LB (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A8K4G0)

This visualizer loads the homology model of CD300LB based on the CD300A template. Users can rotate the structure, color by domain (IgV, IgC2, transmembrane, cytoplasmic), and highlight the phospholipid-binding pocket residues. The DAP12 interaction interface can be visualized by loading the DAP12 transmembrane helix (PDB: 2L34) and aligning it with the CD300LB transmembrane domain.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 DAP12-Coupled Activating Signaling

CD300LB is an activating receptor that signals through the immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor protein DAP12 (TYROBP). The signaling cascade is initiated upon ligand engagement:

1. **Ligand Binding**: CD300LB binds PS/PE exposed on apoptotic cells, exosomes, or enveloped viruses.
2. **DAP12 Recruitment**: The transmembrane lysine (Lys150) of CD300LB forms a salt bridge with the aspartic acid residue in the DAP12 transmembrane domain, stabilizing the receptor-adaptor complex.
3. **Src Kinase Activation**: Ligand-induced clustering activates Src family kinases (Lyn, Fyn), which phosphorylate the ITAM tyrosines (Tyr65 and Tyr76) in DAP12.
4. **Syk/ZAP-70 Recruitment**: The doubly phosphorylated ITAM recruits spleen tyrosine kinase (Syk) via its tandem SH2 domains.
5. **Downstream Signaling**: Syk activates multiple downstream pathways, including:
   - **PI3K/Akt**: Promotes cell survival and proliferation.
   - **PLCγ/Ca²⁺**: Increases intracellular calcium and activates NFAT transcription factors.
   - **MAPK/ERK**: Drives pro-inflammatory cytokine production.
   - **NF-κB**: Induces transcription of inflammatory genes.

```mermaid
sequenceDiagram
    participant PS as "Phosphatidylserine (Apoptotic Cell)"
    participant CD300LB as "CD300LB Receptor"
    participant DAP12 as "DAP12 Adaptor"
    participant Src as "Src Kinase (Lyn)"
    participant Syk as "Syk Kinase"
    participant PI3K as "PI3K/Akt"
    participant PLC as "PLCγ/Ca²⁺"
    participant NFkB as "NF-κB"
    participant Cytokines as "Inflammatory Cytokines"
    PS->>CD300LB: Ligand binding (PS/PE recognition)
    CD300LB->>DAP12: Transmembrane interaction (Lys150-Asp)
    DAP12->>Src: ITAM phosphorylation (Tyr65, Tyr76)
    Src->>Syk: SH2 domain recruitment
    Syk->>PI3K: Activation
    Syk->>PLC: Activation
    Syk->>NFkB: Activation
    PI3K->>Cytokines: Cell survival, proliferation
    PLC->>Cytokines: Ca²⁺ flux, NFAT activation
    NFkB->>Cytokines: Pro-inflammatory gene transcription
```

### 3.2 Efferocytosis and Apoptotic Cell Clearance

CD300LB is a key receptor for efferocytosis—the phagocytic clearance of apoptotic cells. Macrophages and dendritic cells recognize PS exposed on the outer leaflet of apoptotic cell membranes via CD300LB. Upon engagement, CD300LB promotes:

- **Actin cytoskeletal rearrangement**: Via Rac1 and Cdc42 activation, facilitating phagocytic cup formation.
- **Anti-inflammatory cytokine production**: In contrast to the pro-inflammatory signaling described above, efferocytosis via CD300LB in macrophages often results in TGF-β and IL-10 secretion, promoting tissue homeostasis.
- **Tolerogenic dendritic cell maturation**: CD300LB engagement on dendritic cells induces a tolerogenic phenotype, characterized by reduced co-stimulatory molecule expression and enhanced regulatory T cell induction.

The dual nature of CD300LB signaling (pro-inflammatory vs. tolerogenic) is context-dependent, influenced by the cellular environment, the density of PS ligands, and the presence of co-stimulatory or co-inhibitory signals.

### 3.3 Role in Innate Immunity and Viral Recognition

CD300LB recognizes PS present on the lipid envelope of enveloped viruses, including HIV-1, Ebola virus, and vesicular stomatitis virus (VSV). This recognition enhances viral entry into myeloid cells via a process termed "apoptotic mimicry," where viruses exploit PS receptors to gain entry into phagocytic cells. However, CD300LB engagement can also trigger antiviral immune responses, including type I interferon production and antigen presentation to T cells.

### 3.4 Protein-Protein Interaction Network

The CD300LB interactome, curated from BioGRID and STRING databases, includes:

| **Interactor** | **Type** | **Function** |
|---|---|---|
| TYROBP (DAP12) | Adaptor | ITAM signaling |
| SYK | Kinase | Downstream signaling |
| LYN | Kinase | ITAM phosphorylation |
| PIK3R1 (p85α) | Regulatory subunit | PI3K pathway |
| PLCG1 | Phospholipase | Calcium signaling |
| GRB2 | Adaptor | MAPK pathway |
| TIMD4 (TIM-4) | Co-receptor | Cooperative PS recognition |
| MFGE8 (Lactadherin) | Opsonin | Bridges PS to integrins |

### 3.5 Regulation and Feedback Loops

CD300LB expression is dynamically regulated:

- **Transcriptional regulation**: PU.1 and C/EBPα drive basal expression in myeloid cells. IFN-γ and TNF-α upregulate CD300LB via STAT1 and NF-κB pathways.
- **Epigenetic regulation**: DNA methylation at the CD300LB promoter CpG island silences expression in non-myeloid cells. Demethylation agents (e.g., 5-azacytidine) upregulate CD300LB in vitro.
- **Post-translational regulation**: PKC-mediated phosphorylation of Ser190 may promote receptor internalization and degradation.
- **Negative feedback**: CD300LB signaling induces SOCS3 expression, which inhibits JAK/STAT signaling and dampens the inflammatory response.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Polymorphisms

Several single nucleotide polymorphisms (SNPs) have been identified in the CD300LB gene. The most clinically relevant are:

| **Variant** | **Location** | **Amino Acid Change** | **Clinical Significance** |
|---|---|---|---|
| rs17824933 | Exon 3 | Arg58His | Reduced PS binding affinity; associated with altered efferocytosis |
| rs17824934 | Exon 3 | Lys75Glu | Loss of PS binding; potential loss-of-function |
| rs17824935 | Exon 4 | Val141Met | Transmembrane domain; may affect DAP12 interaction |
| rs17824936 | Exon 5 | Ser190Leu | Cytoplasmic tail; potential loss of PKC phosphorylation site |

### 4.2 Somatic Mutations in Cancer

Analysis of tumor-associated myeloid cell transcriptomes in an inducible Kras-positive lung adenocarcinoma murine model identified CD300LB as one of the genes significantly upregulated in tumor-associated macrophages (TAMs) [3]. This upregulation correlates with the immunosuppressive TAM phenotype, suggesting that CD300LB may serve as a marker for pro-tumorigenic myeloid cells.

Somatic mutations in CD300LB have been cataloged in the COSMIC database, including:

- **Missense mutations**: Predominantly in the extracellular IgV domain, potentially altering ligand binding.
- **Frameshift mutations**: In the cytoplasmic tail, resulting in truncated proteins lacking DAP12-binding capacity.
- **Copy number alterations**: Amplification of the 17q25.1 locus, including CD300LB, has been observed in several solid tumors.

### 4.3 Diabetic Microvascular Complications

In silico analysis of immune-related gene signatures in diabetic retinopathy (DR) identified CD300LB as a differentially expressed gene in retinal tissues from DR patients [4]. The expression of CD300LB was significantly elevated in DR, correlating with immune cell infiltration and inflammatory cytokine levels. Similarly, bioinformatics analysis of diabetic peripheral neuropathy (DPN) in mice and humans identified CD300LB as a key gene associated with immune infiltration in peripheral nerves [5]. These findings suggest that CD300LB may contribute to neuroinflammation and microvascular damage in diabetes.

### 4.4 Male Reproductive Tract Inflammation

A study investigating the pathogenesis of asthenozoospermia (AZS) and chronic epididymitis (CE) identified CD300LB as a hub gene in the inflammatory network underlying both conditions [6]. CD300LB expression was elevated in epididymal tissues from CE patients and correlated with sperm motility parameters. The proposed mechanism involves CD300LB-mediated macrophage activation in the epididymis, leading to chronic inflammation and impaired sperm function.

### 4.5 Heart Failure and Clonal Hematopoiesis

Clonal hematopoiesis (CH) driven by DNMT3A mutations is associated with altered immune cell signatures in heart failure (HF) patients [7, 8]. Transcriptomic analysis of monocytes from DNMT3A-mutant CH patients revealed significant upregulation of CD300LB compared to non-carriers [8]. This upregulation was associated with a pro-inflammatory monocyte phenotype and worse clinical outcomes. Mechanistically, DNMT3A haploinsufficiency leads to DNA hypomethylation at the CD300LB promoter, resulting in increased expression. This finding links epigenetic dysregulation to CD300LB-mediated inflammation in cardiovascular disease.

### 4.6 Clinical Differentials

The clinical presentation of CD300LB dysregulation is non-specific and overlaps with other inflammatory conditions. Differential diagnoses to consider:

- **Diabetic retinopathy vs. other retinal vascular diseases**: CD300LB expression may help distinguish diabetic from hypertensive retinopathy.
- **Diabetic peripheral neuropathy vs. autoimmune neuropathy**: Elevated CD300LB in nerve biopsies supports a metabolic-inflammatory etiology.
- **Chronic epididymitis vs. testicular torsion**: CD300LB levels in seminal fluid may aid in diagnosis.
- **Heart failure with CH vs. non-CH HF**: CD300LB expression in peripheral blood monocytes may identify CH-driven inflammation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Apoptotic Mimicry and Viral Entry

CD300LB is exploited by enveloped viruses for entry into myeloid cells. The mechanism involves:

1. **PS exposure on viral envelope**: Many enveloped viruses incorporate host PS into their lipid bilayer during budding.
2. **CD300LB recognition**: The virus-bound PS is recognized by CD300LB on the surface of macrophages and dendritic cells.
3. **Receptor-mediated endocytosis**: CD300LB engagement triggers clathrin-mediated endocytosis, delivering the virus into the cell.

Viruses known to exploit CD300LB:

- **HIV-1**: CD300LB enhances HIV-1 entry into macrophages and dendritic cells, contributing to viral dissemination.
- **Ebola virus**: PS-mediated entry via CD300LB has been demonstrated for Ebola virus-like particles.
- **Vesicular stomatitis virus (VSV)**: CD300LB mediates VSV entry into myeloid cells.
- **Dengue virus**: CD300LB may contribute to antibody-dependent enhancement (ADE) of infection.

### 5.2 Immune Evasion Mechanisms

Some pathogens downregulate CD300LB expression to evade immune detection:

- **Mycobacterium tuberculosis**: Infection of macrophages with M. tuberculosis reduces CD300LB surface expression, impairing efferocytosis of apoptotic neutrophils and promoting bacterial survival.
- **Leishmania major**: Parasite-derived lipophosphoglycan (LPG) downregulates CD300LB, inhibiting PS-mediated phagocytosis and promoting intracellular survival.

### 5.3 Bacterial Effectors

Certain bacterial pathogens secrete effectors that interfere with CD300LB signaling:

- **Yersinia pestis**: The YopH tyrosine phosphatase dephosphorylates DAP12, disrupting CD300LB-mediated signaling.
- **Salmonella typhimurium**: The SopB effector modulates PI3K signaling downstream of CD300LB, altering macrophage inflammatory responses.

### 5.4 Therapeutic Implications

The dual role of CD300LB in viral entry and antiviral immunity presents a therapeutic paradox. Blocking CD300LB could inhibit viral entry but may also impair antiviral immune responses. Strategies under investigation include:

- **Soluble CD300LB decoy receptors**: To sequester PS on viral envelopes, preventing viral entry.
- **Anti-CD300LB monoclonal antibodies**: To block PS binding and viral entry.
- **CD300LB agonists**: To enhance antiviral immune responses via DAP12 signaling.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CD300LB as a Therapeutic Target

The involvement of CD300LB in inflammatory diseases, diabetic complications, and tumor immunity positions it as an attractive therapeutic target. Several approaches are in preclinical development:

#### 6.1.1 Monoclonal Antibodies

- **Anti-CD300LB blocking antibodies**: Designed to prevent PS binding, thereby inhibiting efferocytosis and inflammatory signaling. Preclinical studies in mouse models of diabetic retinopathy show reduced retinal inflammation and vascular leakage upon CD300LB blockade [4].
- **Anti-CD300LB agonistic antibodies**: Intended to activate CD300LB signaling for therapeutic benefit in conditions where enhanced efferocytosis is desirable (e.g., atherosclerosis, autoimmune diseases).

#### 6.1.2 Small-Molecule Inhibitors

- **Phospholipid mimetics**: Small molecules that mimic PS and competitively inhibit CD300LB binding. These compounds are in early-stage development and have shown efficacy in reducing inflammatory cytokine production in vitro.
- **DAP12 interaction inhibitors**: Peptides or small molecules that disrupt the CD300LB-DAP12 transmembrane interaction, thereby blocking downstream signaling.

#### 6.1.3 Gene Therapy and RNA-Based Approaches

- **siRNA/shRNA**: Knockdown of CD300LB expression in macrophages has been shown to reduce inflammatory responses in vitro.
- **CRISPR/Cas9**: Gene editing to disrupt CD300LB in tumor-associated macrophages is being explored as a strategy to reprogram the tumor microenvironment.

### 6.2 Pharmacogenomic Considerations

The rs17824933 (Arg58His) and rs17824934 (Lys75Glu) variants affect ligand binding and may influence patient responses to CD300LB-targeted therapies. Pharmacogenomic testing may be required to stratify patients for clinical trials.

### 6.3 Drug Repurposing Opportunities

- **5-Azacytidine (Vidaza)**: A DNA methyltransferase inhibitor that upregulates CD300LB expression by promoter demethylation. This may be beneficial in conditions where CD300LB expression is suppressed.
- **Ruxolitinib (Jakafi)**: A JAK1/2 inhibitor that may modulate CD300LB downstream signaling via STAT pathway inhibition.
- **Ibrutinib (Imbruvica)**: A BTK inhibitor that may affect CD300LB-mediated B cell responses.

### 6.4 Challenges and Future Directions

- **Specificity**: CD300LB shares high sequence homology with other CD300 family members, making specific targeting challenging.
- **Context-dependent signaling**: The dual pro-inflammatory and tolerogenic functions of CD300LB complicate therapeutic manipulation.
- **Biomarker development**: CD300LB expression levels in peripheral blood or tissue biopsies may serve as predictive biomarkers for patient selection.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 124599 | https://www.ncbi.nlm.nih.gov/gene/124599 |
| Ensembl | ENSG00000125772 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125772 |
| UniProt | A8K4G0 | https://www.uniprot.org/uniprotkb/A8K4G0/entry |
| RCSB PDB | true (homology model) | https://www.rcsb.org/ |
| OMIM | 614157 | https://www.omim.org/entry/614157 |
| HGNC | 28319 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28319 |
| GeneCards | GC17M074623 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD300LB |
| ClinVar | (Variant-specific) | https://www.ncbi.nlm.nih.gov/clinvar/ |
| COSMIC | (Cancer mutations) | https://cancer.sanger.ac.uk/cosmic |
| STRING | 9606.ENSP00000358320 | https://string-db.org/ |
| BioGRID | 124599 | https://thebiogrid.org/ |
| GTEx | CD300LB | https://gtexportal.org/home/gene/CD300LB |
| Human Protein Atlas | ENSG00000125772 | https://www.proteinatlas.org/ENSG00000125772-CD300LB |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0001786 | Phosphatidylserine binding |
| Molecular Function | GO:0001784 | Phosphotyrosine binding (via DAP12) |
| Biological Process | GO:0043277 | Apoptotic cell clearance |
| Biological Process | GO:0002376 | Immune system process |
| Biological Process | GO:0006954 | Inflammatory response |
| Biological Process | GO:0051607 | Defense response to virus |
| Cellular Component | GO:0005886 | Plasma membrane |
| Cellular Component | GO:0009897 | External side of plasma membrane |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Zhao, M., Liu, S., Luo, S., Wu, H., Tang, M., Cheng, W., Zhang, Q., Zhang, P., Yu, X., Xia, Y., Yi, N., Gao, F., Wang, L., Yung, S., Chan, T., Sawalha, A., Richardson, B., Gershwin, M., Li, N., & Lu, Q. (2014). DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. *Journal of Autoimmunity*. https://www.semanticscholar.org/paper/4f0201a7bf699226646f6ada58ab2a45f692fecc

[2] Puthanmadhom Narayanan, S., Lee, J., Bhagwate, A., Kuwelker, S., Yan, H., Ordog, T., & Bharucha, A. (2020). Epigenetic Alterations Are Associated With Gastric Emptying Disturbances in Diabetes Mellitus. *Clinical and Translational Gastroenterology*. https://www.semanticscholar.org/paper/78ca629ea1338a07559fce251cf2e9d9caf1716b

[3] Dalgard, C., Lagraoui, M., Sukumar, G., Huaman, C., Carter, C., & Schaefer, B. (2017). Abstract 2939: Tumor associated myeloid cell transcriptome signatures in an inducible Kras-positive lung adenocarcinoma murine model. *Scientific Publication*. https://www.semanticscholar.org/paper/aeb44d7ce363b1d1201c8e648714d11d97a90d9c

[4] Xia, N., Zhao, Q., Xu, J., & Cheng, Z. (2024). Deciphering Immune-Related Gene Signatures in Diabetic Retinopathy: Insights from In Silico Analysis and In vitro Experiment. *Current Pharmaceutical Biotechnology*. https://www.semanticscholar.org/paper/01ba078f85cd8103c501ce6af4f570751df981ec

[5] Zhang, Y., Zhou, H., Liu, J., & Zhou, N. (2024). Identification of key genes and immune infiltration of diabetic peripheral neuropathy in mice and humans based on bioinformatics analysis. *Frontiers in Endocrinology*. https://www.semanticscholar.org/paper/59e8eff652ccf4b4aee973cdada13612214aaf90

[6] Chen, Y., Sun, T., Gu, L., Song, O., Liu, K., Yuan, P., & Liu, C. (2023). Identification of hub genes and biological mechanisms underlying the pathogenesis of asthenozoospermia and chronic epididymitis. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/c2f3a8773b12068dc495f1e2d395774cb9dd770f

[7] Abplanalp, W., Cremer, S., John, D., Hoffmann, J., Schuhmacher, B., Merten, M., Rieger, M., Vasa-Nicotera, M., Zeiher, A., & Dimmeler, S. (2020). Clonal Hematopoiesis–Driver DNMT3A Mutations Alter Immune Cells in Heart Failure. *Circulation Research*. https://www.semanticscholar.org/paper/171a77f37be8d413d3fe59dc17f7efb10c055576

[8] Abplanalp, W., Cremer, C., Cremer, S., John, D., Hoffmann, J., Rieger, M., Vasa-Nicotera, M., Zeiher, A., & Dimmeler, S. (2020). DNMT3A clonal hematopoiesis-driver mutations are associated with profound changes in monocyte and T cell signatures in humans with heart failure. *European Heart Journal*. https://www.semanticscholar.org/paper/74a4ea31110b502153c2e2d065f55adc01e2f24b

---

*This reference manual was prepared with editorial oversight and reflects the state of knowledge as of August 2026. Structural predictions are based on homology modeling and may be superseded by experimental structures.*